Roivant Sciences (ROIV) news
Recent news
Roivant Sciences exec says Lisraya will be available at list price of $35,000 for a 30-day supply
AInvest Wire · 3d agoRoivant Sciences Ltd: Citigroup raises target price to $46 from $42
Citigroup has raised its price target for Roivant Sciences Ltd. (NASDAQ:ROIV) to $46 from $42, maintaining its Buy rating, according to recent analyst updates. The adjustment reflects optimism surrounding the company’s clinical pipeline and anticipated data catalysts in the second half of 2026,…
AInvest Wire · Aug 10, 2026TD Cowen raises target price to $50 from $41 for Roivant Sciences Ltd
AInvest Wire · Aug 7, 2026Roivant Sciences Q1 adjusted net income USD -243.693 million vs. IBES estimate USD -192.3 million (corrects amount)
Roivant Sciences Ltd. (Nasdaq: ROIV) reported a wider-than-expected loss for the first quarter of 2026, with adjusted net income at -$243.693 million , compared to the IBES estimate of -$192.3 million. The company’s financial performance reflects ongoing investment in its pipeline of therapeutic…
AInvest Wire · Aug 6, 2026Roivant Sciences 1Q loss/share 26c vs. loss/share 33c y/y
Roivant Sciences Ltd. (ROIV) reported first-quarter 2026 loss of $0.26 per share, compared to a loss of $0.33 per share in the same period of the prior year, according to its latest financial results. The improvement in the loss per share reflects ongoing operational adjustments and strategic…
AInvest Wire · Aug 6, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.